The MTN will be holding its final in-country stakeholder meeting for the planned DELIVER (MTN-042) and B-PROTECTED (MTN-043) studies that will be evaluating the safety of the dapivirine vaginal ring and Truvada as oral PrEP in pregnant and breastfeeding women, respectively. The two-day meeting will be taking place in Harare, Zimbabwe, January 28-29, 2020. Similar meetings have already been conducted in Malawi, South Africa, and Uganda. As with previous meetings, the MTN is partnering with AVAC as well as local civil society and NGO partners. These include the Pangea Zimbabwe AIDS Trust and the Organization for Public Health Interventions and Development, working closely with the Zengeza Clinical Research Site of the University of Zimbabwe College of Health Sciences – Clinical Trials Research Centre.